Published in

BioMed Central, BMC Neurology, 1(23), 2023

DOI: 10.1186/s12883-022-03046-w

Links

Tools

Export citation

Search in Google Scholar

B.infantis enhances immunotherapy for Guillain-Barre syndrome through regulating PD-1

Journal article published in 2023 by Peng Shi, Di Nian, Hongdang Qu, Ming Ye, Chun Wang, Li Li, Qian Li
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Abstract Background Guillain-Barré syndrome (GBS) is a rare, autoimmune disease. B.infantis is reported to be effective in alleviating GBS by regulating abnormal function of T helper (Th) cells. Objectives In this study, T cells were isolated from healthy and GBS patients. The therapeutic effect of Bifidobacterium infantis (B.infantis) and whether it is achieved by PD-1 was examined at cellular and animal models. Methods We used CCK-8, flow cytometry and real-time PCR to determine the differentiation of T cell subsets at cellular level. Then, an experimental autoimmune neuritis (EAN) animal model using six-week SD rats (n = 30, male) weighing 180–200 g was established to support the role of B. infantis in GBS through PD-1. Results B. infantis inhibited the proliferation and promoted apoptosis of T cells from GBS. At the same time, the expression levels of PD-1 increased, which was correlated with decreased T-bet (Th1) and ROR-γt (Th17) and increased Foxp3 (Treg) expression. Moreover, B. infantis alleviated the symptoms of GBS. Th1 and Th17 cells decreased while Treg cells increased after B. infantis treatment, which could be partly abrogated by PD-1 inhibitor. Conclusions We concluded from this study that B.infantis alleviated GBS partly through PD-1.